Месипол Drug photo

The description is actual on 23.08.2015

  • Latin name: Mesipol
  • ATH code: M01AC06
  • Active ingredient: Meloksikam
  • Producer: Pharmaceutical plant JSC Polfarm (Poland)


1 ml of solution – 10 mg of a meloksikam.

Additional components: glikofurol, hydroxide and sodium chloride, Megluminum, glycine, half-oxameasures 188, water for infection.

Release form

Mesipol is issued in the form of injection solution for introduction in oil in ampoules on 1,5 ml, on 3 or 5 ampoules in packaging.

Pharmacological action

Anti-inflammatory, analgeziruyushchy (anesthetic), febrifugal.

Pharmacodynamics and pharmacokinetics

Mesipol is medicine from NPVS group in which analgeziruyushchy, antiinflammatory and febrifugal efficiency is inherent. Anti-inflammatory effects of drug are shown thanks to the constraining influence of a meloksikam directed to enzymatic activity of TsOG-2to the enzyme participating in processes of biosynthesis of prostaglandins in the inflamed area. Also, though with smaller productivity, action of a meloksikam is observed concerning TsOG-1enzyme of prostaglandin which is taking part in replication which influences regulation of a renal blood-groove and is characterized by protective function mucous a gastrointestinal tract.

When using in oil to meloksika it is almost completely absorbed. Bioavailability of active ingredient equals 100%. Plasma Cmax, after an injection of 15 mg in oil of drug, is observed in 60 minutes and makes 1,62 mkg/ml.

Communication with plasma proteins (generally with albumine) is carried out for 99%, Vd about 11 liters. Meloksikam passes gistogematichesky barriers and it is found in synovial fluid, in concentration of the making 50% rather plasma.

The full cycle of a metabolism of a meloksikam happens in a liver to allocation of 4 metabolites (inactive). to 5-karboksimeloksika is a key product of a metabolism (60% of the used dose) which forms owing to oxidation of a transitional metabolite of a 5-gidroksimetilmeloksikam (9% of the used dose). Researches of a metabolism of the drug In vitro proved significant influence on this process of an isoenzyme of CYP2C9 and some influence of an isoenzyme of CYP3A4. Two other metabolites (16% and 4% of the used dose), most likely, are formed with participation of the peroxidase which is characterized by individual activity.

The essential enterohepatic address of a meloksikam does not influence its elimination. Removal kidney/intestines is carried out in an approximate ratio 50/50, mainly in the form of metabolites. With the stake which is not changed only 5% of drug are removed, in urine only its trace quantities are defined.

Average T1/2 of a meloksikam equals to 20 hours. The plasma clearance is at the level of 8 ml/min.

Indications to use

Pricks by Mesipol are appointed when carrying out a symptomatic treatment:


Use of drug is absolutely contraindicated at:

  • full or partial combination of bronchial asthma, personal intolerance of NPVS and recuring polypose of okolonosovy bosoms and a nose (including instructions in the anamnesis);
  • gastrointestinal bleedings during the active period;
  • hypersensitivity to a meloksikam or additional ingredients;
  • damages of a gastrointestinal tract of erosive and ulcer character;
  • pregnancies;
  • inflammatory diseases of intestines (including displays of nonspecific ulcer colitis or symptoms of an illness Krone);
  • the progressing renal diseases (including the confirmed hyperpotassemia);
  • to symptomatology of dekompensirovanny heart failure;
  • feeding by a breast;
  • serious pathologies of a liver or kidneys (at KK it is less than 30 ml/min.);
  • bleedings of cerebrovascular or other origin;
  • adaptations during the postoperative period of aortocoronary shunting;
  • aged till 18 years.

With extra care apply at:

  • dislipidemii / lipidemias;
  • cerebrovascular diseases;
  • chronic heart failure;
  • pathologies of peripheral arteries;
  • diabetes mellitus;
  • nicotine addiction;
  • pathologies of kidneys (at KK it is less than 60 ml/min.);
  • identification of Helicobacter pylori;
  • gastrointestinal tract cankers in the anamnesis;
  • long use of NPVS;
  • excessive use of alcoholic beverages;
  • somatopathies of difficult character;
  • parallel reception of peroral glucocorticoids (Prednisolonum), antiagregant (Klopidogrel, Acetylsalicylic acid), anticoagulants (Warfarin), SIOZS (Sertraline, Tsitalopram, Paroksetin, Fluoxetine);
  • at advanced age.

Side effects

System of a hemopoiesis:

  • changes of a blood formula (including a leukopenia and thrombocytopenia);
  • anemia.


  • esophagitis;
  • dyspepsia;
  • eructation;
  • nausea;
  • abdominal pains;
  • vomiting;
  • hyperbilirubinemia;
  • lock;
  • colitis;
  • meteorism;
  • gastritis;
  • diarrhea;
  • stomatitis;
  • activation of enzymes of a liver (passing);
  • damages of a gastrointestinal tract of erosive and ulcer character;
  • bleedings from a gastrointestinal tract (hidden or explicit);
  • hepatitis;
  • perforation of bodies of a gastrointestinal tract.

Urinary system:

  • increase of serumal urea;
  • giperkreatininemiya;
  • acute insufficiency of kidneys;
  • the phenomena of intersticial nephrite, hamaturia, albuminuria (with unspecified communication with use of a meloksikam).



  • epidermal toxic necrolysis;
  • violent rashes;
  • rash/itch of integuments;
  • mnogoformny erythema;
  • small tortoiseshell;
  • photosensitization.

Respiratory system:

  • bronchospasm phenomena.

Cardiovascular system:

Organs of sight:

Allergic manifestations:

Local reactions:

  • burning/pain in an injection venue.

Mesipol, application instruction

Mesipol's ampoules are intended for introduction in oil and are used only for the first 2-3 days of therapy (it is forbidden to enter in/in). In the subsequent reception of peroral forms of a meloksikam (tablet/capsule) is shown.

The recommended daily dose in oil of solution of a meloksikam, according to weight of an inflammation and intensity of a pain syndrome, can make 7,5-15 mg. Administration of drug should be carried out deeply in muscular tissue, as a rule, of buttocks and hips.

Because of possible incompatibility solution of a meloksikam is not mixed in one syringe with other HP.

At heavy pathologies of kidneys (hemodialysis) and the increased risk of forming of by-effects, it is necessary to limit a daily dose of Mesipol to 7,5 mg.

In other cases the maximum dosage of a meloksikam at 24 o'clock is the dose – 15 mg.


At overdose by Mesipol observed: pains in epigastric area, nausea, disturbances of consciousness, gastrointestinal tract bleeding, vomiting, a renal/liver failure, an asystolia, an apnoea.

Carry out treatment to compliance with the revealed symptoms. Use of Colestyraminum which accelerates drug removal is possible. Due to the dense communication with plasma proteins the hemodialysis is ineffective.


Simultaneous use with other HP from NPVS group increases a possibility of bleedings and damages of a gastrointestinal tract of erosive and ulcer character.

Parallel treatment by Mesipol and hypotensive HP can reduce action of the last.

Joint appointment with drugs of lithium can lead to its cumulation and, as a result, to toxic effects. In such cases recommend to control the plasma content of lithium.

At the combined use of a meloksikam with the Methotrexate observed strengthening of side effects of the last in relation to the hemopoietic system (a leukopenia, anemia) that demands periodic carrying out the general blood test.

Use together with diuretic drugs increases risk of development of insufficiency of kidneys.

Parallel therapy by Cyclosporine strengthens nephrotoxic influence of Mesipol.

Efficiency of intrauterine contraceptives can decrease at use of a meloksikam.

At joint therapy with use of anticoagulants (Warfarin, Tiklopidin, Heparin) and trombolitik (Fibrinolysin, Streptokinasa) the possibility of bleedings in this connection control over coagulability of blood is necessary increases.

The combined reception of Colestyraminum, because of binding of a meloksikam, increases its intestinal removal.

Parallel reception of SIOZS raises a possibility of forming of bleedings of a gastrointestinal tract.

Myelotoxic HP increase gematotoksichesky manifestations of Mesipol.

Terms of sale

Upon Mesipol's purchase the recipe of the doctor is obligatory.

Storage conditions

Ampoules with solution in oil need to be stored at a temperature up to 25 °C.

Period of validity

From the moment of production – 2 years.

Special instructions

Care of use of Mesipol, in connection with the increased risk of forming of bleedings of a gastrointestinal tract, is demanded by patients with instructions in the anamnesis on a peptic ulcer of a gastrointestinal tract, and also the sick accepting anticoagulants.

Control of indicators of functionality of kidneys and care of appointment of Mesipol is necessary for patients at advanced age, the patient with cirrhosis, HSN, a circulatory unefficiency and a hypovolemia (because of surgeries).

At pathologies of kidneys (with KK it is more than 25 ml/min.) correction of dosages of a meloksikam is not carried out.

At continuous passing of a hemodialysis the daily dose of Mesipol should not be higher than 7,5 mg.

At parallel reception of diuretics, the patient needs to accept the increased liquid volumes.

At identification of allergic reactions (including itch/rash of integuments, a photosensitization, the small tortoiseshell) it is necessary to stop treatment by Mesipol.

Meloksikam can mask displays of infectious diseases.

When passing therapy by Mesipol it is better to refuse driving of motor transport and performance of exact and/or dangerous works.

Mesipol's analogs


  • Mesipol solution for introduction in oil 10mg/ml 1,5ml amp No. 3. Polfarm Pharmaceutical plant
  • Mesipol solution for introduction in oil 10mg/ml 1,5ml amp No. 5. Polfarm Pharmaceutical plant
to show still


  • Mesipol of 7,5 mg No. 20 of table.
  • Mesipol of 15 mg No. 20 of table.
  • Mesipol of 15 mg No. 10 of table.
to show still
Section: Anesthetics
in more detail

Education: Graduated from the Vinnytsia national medical university of N. I. Pirogov, pharmaceutical faculty, the higher pharmaceutical education – the specialty "Pharmacist".

Experience: Work in Koneks and Bios-Media pharmacy chains as "Druggist". Work as "Pharmacist" in Avicenna pharmacy chain of the city of Vinnytsia.

PAY ATTENTION! Information on drugs on the website is help generalizing, collected from public sources and can form the basis for making decision on use of medicines it is not aware of treatment. Before medicine use Mesipol surely consult with the attending physician.